Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias

Japanese Heart Journal

Volumn 39, Issue 4, 1998, Pages 457-467

  Naitoh, Naoki ^a   Tagawa, Minoru ^a   Yamaura, Masayuki ^a   Taneda, Koji ^a   Furushima, Hiroshi ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

E 4031; MS 551; Refractory period; Reverse use dependent effect

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; NIFEKALANT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; QT INTERVAL;

EID: 0031821226     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.39.457     Document Type: Article

References (23)

1. Colatsky JJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235-42.
2. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action. Circ Res 1991; 68: 77-84.
3. Sawada K, Nomoto K, Hiraoka M. Effects of a novel class 3 antiarrhythmic agent, E-4031, on ventricular arrhythmias [Abstract]. Jpn Circ J 1988; 52: 919.
4. Katoh H, Ogawa S, Furuno I, Yoh S, Saeki K, Nakamura Y. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on reentrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther 1990; 253: 1077-82.
5. Inoue H, Yamashita T, Usui M, Nozaki A, Saihara S, Sugimoto T. Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenon. J Cardiovasc Pharmacol 1991; 18: 137-43.
6. Fujiki A, Tani M, Mizumaki K, Shimono M, Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1994; 23: 374-8.
7. + current is composed of two currents in guinea pig atrial cells. Am J Physiol 1991; 260: H393-9
8. + current: Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 194-214.
9. Argentieri TM, Carroll MS, Sullivan ME. Cellular electrophysiologic effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissue. J Cardiovasc Pharmacol 1991; 18: 167-74.
10. Sager TP, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness: electrophysiologic actions of sematilide HCL in humans. Circulation 1993; 88: 1072-82.
11. Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation 1994; 90: 1811-9.
12. Hondeghem LAM and Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81: 686-90.
13. Aizawa Y, Niwano S, Chinushi M, et al. Incidence and mechanism of interruption of reentrant ventricular tachycardia with rapid ventricular pacing. Circulation 1992; 85: 589-95.
14. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug doietilide on ventricular monophasic action. Am J Cardiol 1992; 70: 1432-7.
15. Katoh R, Ikeda N, Yabek SM, Kannan R, Singh BN. Electrophysiologic effects of the Levo- and Dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmakokinetics. J Am Coll Cardiol 1986; 7: 116-25.
16. + current by dofetilide. Circ Res 1993; 72: 75-83
17. Spinelli W, Moubarak IF, Parsons RW, Colatsky TJ. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of Ik block and lack of reverse use dependence in cat ventricular myocytes. Cardiovasc Res 1993; 27: 1580-91.
18. Rees SA, Curtis MJ. Specific Ik 1 blockade: A new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit, and primate. Circulation 1993; 87: 1979-89.
19. Nabauer M, Beuckelmann DJ, Erdmann E. Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res 1993; 87: 1979-89.
20. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063-71.
21. Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation 1994; 90: 1811-9.
22. Balser JR, Bennett PB, Hondeghem LM, Roden DM. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res 1991; 69: 519-29.
23. Lynch JJ, Heaney LA, Wallace AA, Gehret JR, Selnich HG, Stein RB. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E-4031 in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990; 15: 764-75.